[{"id":"98c1a72a-f82b-4bd2-a82b-8f84a4d24528","acronym":"","url":"https://clinicaltrials.gov/study/NCT04171219","created_at":"2021-01-18T20:20:56.539Z","updated_at":"2025-02-25T15:11:22.085Z","phase":"Phase 2","brief_title":"Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers","source_id_and_acronym":"NCT04171219","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • talabostat (BXCL701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 03/19/2020","start_date":" 03/19/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-13"}]